Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report issued on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Separately, Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. Nine analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $8.39.

Revance Therapeutics Stock Performance

Shares of RVNC stock opened at $3.65 on Monday. The stock has a 50 day simple moving average of $3.65 and a 200-day simple moving average of $3.77. The company has a market cap of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.90. Revance Therapeutics has a 12-month low of $2.30 and a 12-month high of $6.65.

Institutional Investors Weigh In On Revance Therapeutics

Large investors have recently added to or reduced their stakes in the business. Natixis purchased a new stake in shares of Revance Therapeutics in the fourth quarter valued at about $31,000. Two Sigma Securities LLC acquired a new position in shares of Revance Therapeutics during the 4th quarter worth approximately $35,000. Alpine Global Management LLC purchased a new stake in Revance Therapeutics in the 4th quarter valued at approximately $37,000. RPO LLC acquired a new stake in Revance Therapeutics during the 4th quarter valued at $55,000. Finally, Fairfax Financial Holdings Ltd. Can purchased a new position in Revance Therapeutics during the fourth quarter worth $64,000. 97.70% of the stock is owned by institutional investors and hedge funds.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.